Acute ischaemic stroke
Large randomized programmes have tested Cerebrolysin alongside standard stroke care.
Explore the research →NEURORECOVERY & STROKE RESEARCH
Cerebrolysin
A neurological treatment and research compound studied for stroke recovery, cognition and brain injury, with mixed findings across human trials.
Acute strokeMotor rehabilitationCognitive disorders
Multiple human trials, but systematic-review conclusions remain uncertainSome rehabilitation-focused trials report improved motor outcomes, while the largest acute-stroke study was neutral overall and the 2023 Cochrane review did not establish a clear clinical benefit.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Where has Cerebrolysin been tested in people?
Cerebrolysin attracts interest because its research centres on protecting vulnerable brain cells and supporting recovery after neurological damage. That has led to human studies in stroke, rehabilitation, memory problems and brain injury — areas where even modest improvements can matter greatly.
Motor rehabilitation
The clearest positive signal comes from early post-stroke motor-recovery studies combined with rehabilitation.
Explore the research →Cognition and dementia
Trials and reviews have explored vascular dementia and Alzheimer's disease outcomes.
Explore the research →Multi-peptide neurotrophic mixture
The product is proposed to influence neurotrophic, inflammatory and repair pathways rather than a single receptor.
Explore the research →THE SCIENCE BIT
A peptide mixture with several neural research angles.
Cerebrolysin contains a mixture of small peptides and amino acids, rather than one defined peptide with one receptor. Its experimental work explores neurotrophic-like activity and neuronal responses to injury.
That makes the biology broader but also harder to reduce to a single mechanism. Clinical results vary between acute stroke, rehabilitation and cognition studies.
See the studies & trials →- Peptide mixture
- Many components
- Neurotrophic-like effects
- Cell-support research
- Clinical setting
- Outcomes differ between studies
How this connects to the research
Mixed human outcomes; no single defined receptor mechanism.
FROM MOLECULE TO TISSUE
Where Cerebrolysin connects with the body
These are the tissues and biological systems behind the interest in Cerebrolysin.
- Brain
- Stroke and cognition research.
- Motor pathways
- Rehabilitation studies.
- Neurons
- Experimental protection signals.
The research behind the interest
Acute ischaemic stroke
Large randomized programmes have tested Cerebrolysin alongside standard stroke care.
CASTA did not show a significant overall benefit on its primary clinical outcome, although subgroup findings have continued to motivate research.
Mixed human evidenceExplore the studies →Motor rehabilitation
The clearest positive signal comes from early post-stroke motor-recovery studies combined with rehabilitation.
CARS reported better Action Research Arm Test scores after a 21-day IV course, but replication and review-level certainty remain limited.
Promising condition-specific human evidenceExplore the studies →Cognition and dementia
Trials and reviews have explored vascular dementia and Alzheimer's disease outcomes.
Some analyses report cognitive signals, but heterogeneity, regional use and study quality prevent a broad cognitive-treatment claim.
Mixed human evidenceExplore the studies →Multi-peptide neurotrophic mixture
The product is proposed to influence neurotrophic, inflammatory and repair pathways rather than a single receptor.
That breadth may be biologically interesting, but the mixture makes exposure, manufacturing consistency and mechanism less simple than a defined peptide sequence.
Mechanistic + product-level complexityExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableCASTA: Cerebrolysin in acute ischaemic stroke in Asia ↗
1,070 patients with acute ischaemic stroke
Intravenous · 30 mL daily10 days
The primary overall outcome did not differ significantly between Cerebrolysin and placebo.
Exploratory findings in more severely affected participants were hypothesis-generating rather than definitive.
CARS: Cerebrolysin and early motor rehabilitation after stroke ↗
208 patients with severe arm motor impairment after acute ischaemic stroke
Intravenous · 30 mL daily21 days, started 24–72 hours after stroke
The trial reported greater improvement on the Action Research Arm Test with Cerebrolysin plus rehabilitation.
The result supports further motor-recovery research but does not establish unsupervised use or prevention.
Cochrane review: Cerebrolysin for acute ischaemic stroke ↗
Seven trials involving 1,773 participants
The review did not find evidence of reduced all-cause mortality or a clear overall clinical benefit.
It raised concern about non-fatal serious adverse events and judged important evidence low or very low certainty.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
Numerous randomized human studies exist across stroke and cognitive disorders.
✓
Clinical efficacyLimited
2/5 evidence depth
Individual positive studies are offset by neutral large trials and uncertain systematic-review conclusions.
◇
Safety evidenceDeveloping
3/5 evidence depth
Short IV courses provide useful adverse-event data, but product, route and population-specific risks remain.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Animal and cell research supports neurotrophic and post-injury repair mechanisms.
HOW TO READ THESE SCORESStrong preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPECerebrolysinMechanism → measured response → clinical outcome
Randomized studies across stroke and cognition
Positive condition-specific signals; neutral overall evidence
Who benefits, optimal course and serious-event balance
Keep route, study setting and outcome together
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Cerebrolysin
Community interest centres on post-stroke recovery, traumatic brain injury, memory and a perceived 'brain repair' effect. Unlike many wellness peptides, Cerebrolysin has human trials—but those trials do not support a single general neurorestoration claim.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Recovery after stroke or brain injury
People are interested in regaining mobility, independence or cognitive function. The practical outcomes are specific and important, but recovery stories also include rehabilitation, time and many background treatments.
- What makes a report informative
- Validated functional measures and the rehabilitation context.
- What can muddy the picture
- Natural recovery and rehabilitation make uncontrolled accounts difficult to interpret.
Memory and mental clarity
Cognitive interest includes remembering information and feeling less mentally slowed. This is a different question from improving function after a neurological injury.
- What makes a report informative
- Familiar cognitive tasks and everyday independence.
- What can muddy the picture
- Findings in neurological patients do not establish enhancement in healthy adults.
Longer-term neurological resilience
Some interest is preventive or centred on repeated courses. A sense of feeling sharper after a course does not show that future decline has been prevented.
- What makes a report informative
- Persistence of functional change and the full treatment history.
- What can muddy the picture
- The mixture, study setting and mixed trial results matter more than broad neuroprotection claims.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Post-stroke motor recovery
This is the most clinically grounded area of interest and is usually discussed alongside active rehabilitation.
Human findings & limits
CARS reported a positive upper-limb motor signal, while CASTA and review-level evidence were less convincing overall.
Laboratory & animal context
Stroke models support neurogenesis, plasticity and injury-response mechanisms.
What this means: Promising in a defined rehabilitation context, but not settled standard-of-care evidence.
Memory and mental clarity
People report subjective changes in recall, processing speed or mental fatigue during short courses.
Human findings & limits
Dementia studies are mixed and do not establish enhancement in healthy users.
Laboratory & animal context
Neurotrophic and synaptic-plasticity models offer a rationale.
What this means: A broader community claim than the condition-specific human evidence supports.
Brain-injury recovery
Traumatic brain injury discussions often borrow from stroke and older injury studies.
Human findings & limits
Small and heterogeneous TBI studies prevent a reliable universal protocol.
Laboratory & animal context
Injury models support anti-inflammatory and repair hypotheses.
What this means: Research interest is reasonable; diagnosis, severity and rehabilitation setting remain decisive.
Short injectable courses
Users discuss IM or IV courses rather than continuous daily wellness use.
Human findings & limits
Trials establish that specific IV courses have been administered under medical supervision.
Laboratory & animal context
Animal dosing does not validate retail product concentration or home injection.
What this means: A recognizable course structure, but route, indication and clinical supervision cannot be stripped away.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA community IM course beside—not derived from—the clinical IV protocols
Cerebrolysin is a complex prescription-style injectable product in some countries. The community pattern below is not a conversion of the 30 mL hospital infusions used in stroke trials.
1Week 1
5 mL · once dailyAnecdotal IM starting pattern
2Weeks 2–3
5 mL · 5 days/weekRecurring community frequency
3Week 4
Complete or stopNo validated wellness extension
4After course
Pause & clinical reviewNo universal maintenance interval
What people commonly discuss5 mL intramuscularly once daily, five days per week for about four weeks, appears in community and regional-practice summaries.
What remains unvalidatedNo controlled trial validates this pattern for healthy cognition, mental clarity or general brain recovery. Injection and large-volume delivery require clinical oversight.
ROUTE & DELIVERYPublished stroke protocols were supervised IV infusions
CASTA used 30 mL daily for 10 days and CARS used 30 mL daily for 21 days in acute stroke care. Those protocols are not home-use targets.
PROFESSIONAL SOURCE CONTEXT
CARS randomized motor-recovery trial ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Published Cerebrolysin protocols are clinician-administered IV courses tied to acute neurological care; they are not general wellness regimens.
PUBLISHED HUMAN RESEARCH
View source ↗CASTA acute-stroke trial ↗
Hospitalized patients with acute ischaemic stroke
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Hospitalized patients with acute ischaemic stroke. Route: Given slowly into a vein (IV infusion). The study lasted 10 days. The figures below describe the research design, not a personal schedule.
| First amount studied | 30 mL |
|---|---|
| How often? | Once daily |
| How was it given? | Given slowly into a vein (IV infusion) |
| How long? | 10 days |
See the exact study wording +
Start / initial: 30 mL
End / target: 30 mL
Frequency: Once daily
Route: Intravenous infusion
Study duration: 10 days
Source: CASTA trial ↗
No significant overall primary-outcome benefit was demonstrated.
PUBLISHED HUMAN RESEARCH
View source ↗CARS motor-recovery trial ↗
Patients beginning early post-stroke rehabilitation
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Patients beginning early post-stroke rehabilitation. Route: Given slowly into a vein (IV infusion). The study lasted 21 days. The figures below describe the research design, not a personal schedule.
| First amount studied | 30 mL |
|---|---|
| How often? | Once daily |
| How was it given? | Given slowly into a vein (IV infusion) |
| How long? | 21 days |
See the exact study wording +
Start / initial: 30 mL
End / target: 30 mL
Frequency: Once daily
Route: Intravenous infusion
Study duration: 21 days
Source: CARS trial ↗
This was hospital-linked adjunctive care started 24–72 hours after stroke, not a self-use schedule.
COMMUNITY DISCUSSION
Anecdotal / region-specific · route and indication matterWhat people commonly discuss
STARTING APPROACHES
Community and regional practice discussions often describe 5 mL intramuscularly once daily, or clinician-led IV courses using larger volumes.
DURATION / CYCLES
Five days per week for about four weeks is a recurring non-trial pattern; published stroke trials instead used daily IV dosing for 10–21 days.
MAINTENANCE DISCUSSION
Repeat monthly courses are discussed, but no universal evidence-based maintenance or break schedule exists across cognition, recovery or wellness goals.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Clinical solution guide
Human trials · formulation-specificClinical research reports the commercial solution in millilitres. A research vial labelled in milligrams is not interchangeable with that solution. Record the actual clinical volume and dates; no mg-to-mL conversion is inferred from the product name.
Form and route: Clinical Cerebrolysin solution, studied intravenously
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Cerebrolysin
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDCerebrolysin
→
OFTEN EXPLORED WITHCerebrolysin + stroke rehabilitation
Cerebrolysin + Task-specific multidisciplinary rehabilitation
→
OFTEN EXPLORED WITHCerebrolysin + cognitive rehabilitation
Cerebrolysin + Clinician-led cognitive therapy
→
OFTEN EXPLORED WITHCerebrolysin + Semax
Cerebrolysin + Semax
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
CCEREBROLYSIN IS USUALLY DISCUSSED AROUNDNeurorecovery research in acute neurological conditions
＋The strongest positive signal is tied to an early post-stroke rehabilitation protocol, not general cognitive enhancement.
PTHE PAIRED APPROACH MAY ADDStructured rehabilitation or another neuroactive peptide
Rehabilitation belongs to the tested clinical context. Semax is a community pairing without controlled combination evidence.
＋
OFTEN EXPLORED WITH
Explore →＋Cerebrolysin + stroke rehabilitation
Cerebrolysin + Task-specific multidisciplinary rehabilitationWHY IT IS EXPLOREDThe strongest positive trial signal was observed when the product was added to early structured motor rehabilitation.
Condition-specific clinical research; it must not delay emergency stroke treatment or replace rehabilitation.OFTEN EXPLORED WITH
Explore →＋Cerebrolysin + cognitive rehabilitation
Cerebrolysin + Clinician-led cognitive therapyWHY IT IS EXPLOREDPeople hope a neurotrophic intervention could support learning during structured recovery.
Plausible rehabilitation rationale; combination-specific benefit is not established across diagnoses.OFTEN EXPLORED WITH
Explore →Cerebrolysin + Semax
Cerebrolysin + SemaxWHY IT IS EXPLOREDCommunity stacks pair two different neuroprotection narratives.
No controlled human trial validates benefit, neuropsychiatric safety or dosing of the combination.01Keep emergency care first
Stroke or new focal neurological symptoms require immediate evidence-based assessment.
02Separate diagnosis from enhancement
Recovery after injury is not equivalent to improving focus in a healthy user.
03Watch combined CNS effects
Headache, agitation, sleep change, seizure risk and medication interactions may become harder to attribute.
Safety context
SAFETY & UNCERTAINTY
A complex injectable mixture belongs in a diagnosis- and route-specific clinical context
01ENCOURAGING CONTEXTShort clinical IV courses have been studied
Randomized stroke trials provide human tolerability and adverse-event data in monitored medical settings.
02THE IMPORTANT BOUNDARYClinical results remain mixed
A positive motor-rehabilitation signal coexists with a neutral large acute-stroke trial and uncertain review-level benefit.
03WHAT REMAINS UNKNOWNWho benefits and the serious-event balance
Optimal patient selection, repeat courses, healthy-user effects, interactions and product-specific long-term safety remain unsettled.
What the current evidence saysCerebrolysin has short-course trial exposure, but acute neurological symptoms require emergency assessment and evidence-based care. Seizure history, kidney function, allergy risk, interactions, infusion reactions and product provenance deserve particular attention; a systematic review also raised uncertainty around non-fatal serious adverse events.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Face or limb weakness, speech change, sudden severe headache or confusion requires immediate emergency care.
A complex porcine-derived mixture raises allergy, provenance, storage and administration questions beyond a single synthetic sequence.
Neurological history, infusion reactions and concurrent CNS-active treatment can materially alter risk.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
8 sourcesSources used on this profile
Original publicationCASTA: Cerebrolysin in acute ischaemic stroke in AsiaJournal / DOI ↗Bibliographic recordCASTA: Cerebrolysin in acute ischaemic stroke in AsiaPubMed ↗Original publicationCARS: Cerebrolysin and early motor rehabilitation after strokeJournal / DOI ↗Bibliographic recordCARS: Cerebrolysin and early motor rehabilitation after strokePubMed ↗Original publicationCochrane review: Cerebrolysin for acute ischaemic strokeJournal / DOI ↗Bibliographic recordCochrane review: Cerebrolysin for acute ischaemic strokePubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Cerebrolysin is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.